Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BSE - Delayed Quote INR

Bal Pharma Limited (BALPHARMA.BO)

Compare
106.36
+1.83
+(1.75%)
At close: 3:28:03 PM GMT+5:30
Loading Chart for BALPHARMA.BO
  • Previous Close 104.53
  • Open 102.53
  • Bid 105.10 x --
  • Ask 107.40 x --
  • Day's Range 102.53 - 107.40
  • 52 Week Range 76.30 - 157.90
  • Volume 115
  • Avg. Volume 9,258
  • Market Cap (intraday) 1.693B
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) 21.84
  • EPS (TTM) 4.87
  • Earnings Date May 26, 2025 - May 30, 2025
  • Forward Dividend & Yield 1.20 (1.15%)
  • Ex-Dividend Date Sep 18, 2024
  • 1y Target Est --

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

www.balpharma.com

868

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BALPHARMA.BO

View More

Performance Overview: BALPHARMA.BO

Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

BALPHARMA.BO
13.46%
S&P BSE SENSEX (^BSESN)
1.62%

1-Year Return

BALPHARMA.BO
10.97%
S&P BSE SENSEX (^BSESN)
8.65%

3-Year Return

BALPHARMA.BO
4.46%
S&P BSE SENSEX (^BSESN)
37.12%

5-Year Return

BALPHARMA.BO
149.32%
S&P BSE SENSEX (^BSESN)
159.19%

Compare To: BALPHARMA.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BALPHARMA.BO

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    1.66B

  • Enterprise Value

    2.95B

  • Trailing P/E

    21.46

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.54

  • Price/Book (mrq)

    2.42

  • Enterprise Value/Revenue

    0.97

  • Enterprise Value/EBITDA

    9.02

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.36%

  • Return on Assets (ttm)

    4.20%

  • Return on Equity (ttm)

    11.64%

  • Revenue (ttm)

    3.24B

  • Net Income Avi to Common (ttm)

    76.63M

  • Diluted EPS (ttm)

    4.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    247.15M

  • Total Debt/Equity (mrq)

    228.36%

  • Levered Free Cash Flow (ttm)

    5.43M

Research Analysis: BALPHARMA.BO

View More

Company Insights: BALPHARMA.BO

Research Reports: BALPHARMA.BO

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.